3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Motor Activity
32
Breast Neoplasms
21
Neoplasms
17
Prostatic Neoplasms
11
Obesity
8
Colorectal Neoplasms
6
Sarcopenia
5
Pancreatic Neoplasms
5
Lung Neoplasms
5
Polycystic Ovary Syndrome
4
Head and Neck Neoplasms
4
Signs and Symptoms
3
Multiple Myeloma
3
Lymphedema
3
Inflammation
3
Fatigue
3
Diabetes Mellitus, Type 2
3
Colonic Neoplasms
3
Brain Neoplasms
3
Uterine Cervical Neoplasms
2
Pharyngeal Neoplasms
2
Overweight
2
Osteoporosis, Postmenopausal
2
Osteoporosis
2
Lymphoma
2
Leukemia, Myeloid, Acute
2
Leukemia
2
Laryngeal Neoplasms
2
Insulin Resistance
2
Endometrial Neoplasms
2
Interventions
Cyclophosphamide
82
Imatinib Mesylate
81
fludarabine phosphate
67
fludarabine
62
Whole-Body Irradiation
55
Mycophenolic Acid
54
Tacrolimus
42
nilotinib
40
Busulfan
39
Dasatinib
32
Cyclosporine
30
Peripheral Blood Stem Cell Transplantation
28
thymoglobulin
25
Melphalan
25
Thiotepa
24
Cytarabine
24
Granulocyte Colony-Stimulating Factor
23
Antilymphocyte Serum
23
Methotrexate
21
Filgrastim
21
Stem Cell Transplantation
20
ponatinib
16
Sirolimus
16
sargramostim
14
Cord Blood Stem Cell Transplantation
13
Rituximab
11
Cyclosporins
11
Clofarabine
11
venetoclax
10
peginterferon alfa-2b
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
×
Resistance Training
×
Clear all
NCT07518940
2026-04-09
ENERGIA
University of Turin, Italy
Phase NA
Not yet recruiting
25 enrolled